Fig. 2From: Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trialPercentage change in PSA from baseline. A Maximum decrease of PSA from baseline. B Decrease of PSA at week 12 from baseline. C Decrease of PSA at week 12 by dose. Two patients from 240 mg group with only baseline PSA results but no post-baseline PSA results were not included in the waterfall plotsBack to article page